Aclaris Therapeutics, Inc. ACRS
Regular-session close
After hours · Nov 20, 7:03 PM ET
- YTD
- +14.29%
- 1 year
- +42.74%
5D -0.19 (-5.23%)
- Market cap
- 545.63M
- Revenue (ttm)
- 27.08M
- Profit margin
- -136.65%
- EPS (ttm)
- -0.59
- Shares out
- 107.02M
- Forward P/E
- -5.00
- YTD return
- +14.29%
- 1-year return
- +42.74%
- 50-day average
- 2.70
- Volume
- 2.19M
- Avg volume
- 3.07M
- Open
- 3.44
- Previous close
- 3.50
- Day's range
- 3.40 – 3.54
- 52-week range
- 2.41 – 6.53
- Beta
- 0.12
- Analysts
- Buy
- Price target
- 10.00 (+190.7%)
Key statistics
- 200-day average
- 1.58
- Enterprise value
- 68.82M
- Price / sales
- 11.46
- Price / book
- 1.59
- Revenue growth
- -53.20%
- Free cash flow
- -22.05M
- Total cash
- 127.72M
- Total debt
- 2.25M
- Return on equity
- -25.83%
- Short % of float
- 4.14%
Fundamental scorecard
6 of 25 checks passed on ACRS’s reported financials
6of 25 checks passed
- Value 0 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 6, 2024 | Sep 1, 2024 | -0.08 | -0.11 | -0.03 | -37.50% |
| Aug 7, 2024 | Jun 1, 2024 | -0.19 | -0.15 | +0.04 | +21.05% |
| May 7, 2024 | Mar 1, 2024 | -0.28 | -0.24 | +0.04 | +14.29% |
| Feb 27, 2024 | Dec 1, 2023 | -0.37 | -0.30 | +0.07 | +18.92% |
| Nov 6, 2023 | Sep 1, 2023 | -0.48 | -0.41 | +0.07 | +14.58% |
| Aug 7, 2023 | Jun 1, 2023 | -0.45 | -0.42 | +0.03 | +6.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 23, 2024 | HC Wainwright & Co. | up | Neutral | Buy |
| Nov 19, 2024 | Leerink Partners | up | Market Perform | Outperform |
| Nov 19, 2024 | Jefferies | up | Hold | Buy |
| Nov 19, 2024 | BTIG | up | Neutral | Buy |
| Nov 18, 2024 | Piper Sandler | up | Neutral | Overweight |
| Sep 17, 2024 | HC Wainwright & Co. | reit | — | Neutral |
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- aclaristx.com
News
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Stock Has Consensus Price Target of $10.67 Canaccord Genuity Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $12
This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday Wedbush Downgrades Aclaris Therapeutics to Neutral, Lowers Price Target to $3
Red Cat Downbeat Q3 Results, Joins Omeros, Deutsche Bank And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
Why is Aclaris Therapeutics Stock Trading Lower on Monday?
Why is Aclaris Therapeutics Stock Trading Lower on Monday?
Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
Your note
Sign in to keep a note on ACRS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BALTHASER KEVIN J | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 29, 2024 | 24,697 |
| HUMPHRIES WILLIAM DOUGLAS | Director | Conversion of Exercise of derivative security | May 30, 2024 | 28,732 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | Aug 4, 2024 | 0 |
| MEHRA ANAND | Director | Purchase | Nov 18, 2024 | 710,030 |
| MILANO VINCENT J | Director | Conversion of Exercise of derivative security | May 30, 2024 | 12,523 |
| MOLINEAUX CHRISTOPHER P | Director | Conversion of Exercise of derivative security | May 30, 2024 | 53,163 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BML Capital Management, LLC | 13.32% | 14,250,000 | 41.33M | Sep 29, 2024 |
| Vanguard Group Inc | 4.38% | 4,685,498 | 13.59M | Sep 29, 2024 |
| Shaw D.E. & Co., Inc. | 3.15% | 3,371,849 | 9.78M | Sep 29, 2024 |
| Millennium Management Llc | 2.81% | 3,005,598 | 8.72M | Sep 29, 2024 |
| Rock Springs Capital Management, LP | 2.57% | 2,753,495 | 7.99M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 2.30% | 2,458,873 | 7.13M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.98% | 2,115,428 | 6.13M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.77% | 820,732 | 2.38M | Sep 29, 2024 |
| Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 0.66% | 706,504 | 2.05M | Sep 29, 2024 |
| Vanguard Variable Insurance Fund-Small Company Growth | 0.60% | 639,021 | 1.85M | Sep 29, 2024 |
| iShares Biotechnology ETF | 0.46% | 491,473 | 1.43M | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.38% | 403,786 | 1.17M | Oct 30, 2024 |
